Role of PARP1-Mediated Autophagy in EGFR-TKI Resistance in Non-Small Cell Lung Cancer

The authors explored the role of PARP1-mediated autophagy in the progression of tyrosine kinase inhibitor therapy. PARP1-mediated autophagy was evaluated in vitro by CCK-8 assay, clonogenic assay, immunofluorescence, and western blot in the HCC-827, H1975, and H1299 cells treated with icotinib, rapamycin, and AZD2281 alone or in combination.
[Scientific Reports]
Zhang, Z., Lian, X., Xie, W., Quan, J., Liao, M., Wu, Y., Yang, Z.-Z., & Wang, G. (2020). Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer. Scientific Reports, 10(1), 20924. https://doi.org/10.1038/s41598-020-77908-z Cite
Full Article
Bookmark

No account yet? Register

0
Share

CBL0137 Increases the Targeting Efficacy of Rovalpituzumab Tesirine against Tumor-Initiating Cells in Small Cell Lung Cancer

Researchers investigated the potential effect of combining Rovalpituzumab tesirine and CBL0137 in small cell lung cancer to eradicate tumor-initiating cells more effectively.
[British Journal of Cancer]
Lindner, D. J., Wildey, G., Parker, Y., Dowlati, A., Stark, G. R., & De, S. (2020). CBL0137 increases the targeting efficacy of Rovalpituzumab tesirine against tumour-initiating cells in small cell lung cancer. British Journal of Cancer, 1–3. https://doi.org/10.1038/s41416-020-01192-x Cite
Abstract
Bookmark

No account yet? Register

0
Share

Ipsen Receives FDA Fast Track Designation for Investigational Irinotecan Liposome Injection (ONIVYDE®) as a Second-Line Monotherapy Treatment for Small Cell Lung Cancer (SCLC)

Ipsen announced the FDA has granted the company Fast Track designation for irinotecan liposome injection in study patients with SCLC who progressed following a first-line platinum-based regimen, reflecting the unmet medical need.
[Ipsen]
Press Release
Bookmark

No account yet? Register

0
Share

CCL7 Recruits cDC1 to Promote Antitumor Immunity and Facilitate Checkpoint Immunotherapy to Non-Small Cell Lung Cancer

Researchers demonstrated that CCL7 facilitated anti-PD-1 therapy for the KrasLSL−G12D/+Tp53fl/fl and the KrasLSL−G12D/+Lkb1fl/fl NSCLC mouse models by recruiting conventional DC 1 into the TME to promote T cell expansion.
[Nature Communications]
Zhang, M., Yang, W., Wang, P., Deng, Y., Dong, Y.-T., Liu, F.-F., Huang, R., Zhang, P., Duan, Y.-Q., Liu, X.-D., Lin, D., Chu, Q., & Zhong, B. (2020). CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer. Nature Communications, 11(1), 6119. https://doi.org/10.1038/s41467-020-19973-6 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Genprex Initiates Site Recruitment for Acclaim-1 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer

Genprex, Inc. announced it has commenced clinical trial site recruitment for its upcoming Acclaim-1 clinical trial for the treatment of non-small cell lung cancer. Acclaim-1 is an open-label, multi-center Phase 1/2 clinical trial that combines Genprex’s lead drug candidate, REQORSA™ immunogene therapy with AstraZeneca PLC’s Tagrisso.
[Genprex, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

Therapeutic Targeting of Metadherin Suppresses Colorectal and Lung Cancer Progression and Metastasis

Using genetically modified mouse models of spontaneous colorectal and lung cancers, researchers found that MTDH promotes cancer progression by facilitating Wnt activation and by inducing cytotoxic T cell exhaustion, respectively.
[Cancer Research]
Shen, M., Xie, S., Rowicki, M., Michel, S., Wei, Y., Hang, X., Wan, L., Lu, X., Yuan, M., Jin, J. F., Jaschinski, F., Zhou, T., Klar, R., & Kang, Y. (2020). Therapeutic Targeting of Metadherin Suppresses Colorectal and Lung Cancer Progression and Metastasis. Cancer Research. https://doi.org/10.1158/0008-5472.CAN-20-1876 Cite
Abstract
Bookmark

No account yet? Register

0
Share

The Hexosamine Biosynthesis Pathway Is a Targetable Liability in KRAS/LKB1 Mutant Lung Cancer

Glutamine-fructose-6-phosphate transaminase [isomerizing] 2 inhibition selectively reduced KRAS/LKB1 co-mutant tumour cell growth in culture, xenografts and genetically modified mice.
[Nature Metabolism]
Kim, J., Lee, H. M., Cai, F., Ko, B., Yang, C., Lieu, E. L., Muhammad, N., Rhyne, S., Li, K., Haloul, M., Gu, W., Faubert, B., Kaushik, A. K., Cai, L., Kasiri, S., Marriam, U., Nham, K., Girard, L., Wang, H., … DeBerardinis, R. J. (2020). The hexosamine biosynthesis pathway is a targetable liability in KRAS / LKB1 mutant lung cancer. Nature Metabolism, 1–12. https://doi.org/10.1038/s42255-020-00316-0 Cite
Abstract
Bookmark

No account yet? Register

0
Share

CCL7 Recruits cDC1 to Promote Antitumor Immunity and Facilitate Checkpoint Immunotherapy to Non-Small Cell Lung Cancer

Researchers demonstrated that CCL7 facilitates anti-PD-1 therapy for the KrasLSL−G12D/+Tp53fl/fl and the KrasLSL−G12D/+Lkb1fl/fl non-small cell lung cancer mouse models by recruiting conventional DC 1 (cDC1) into the tumor microenvironment to promote T cell expansion.
[Nature Communications]
Zhang, M., Yang, W., Wang, P., Deng, Y., Dong, Y.-T., Liu, F.-F., Huang, R., Zhang, P., Duan, Y.-Q., Liu, X.-D., Lin, D., Chu, Q., & Zhong, B. (2020). CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer. Nature Communications, 11(1), 6119. https://doi.org/10.1038/s41467-020-19973-6 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Altered Mitochondria Functionality Defines a Metastatic Cell State in Lung Cancer and Creates an Exploitable Vulnerability

Metastasis-derived cell lines in vitro and metastases analyzed ex vivo from an autochthonous lung cancer mouse model had lower mitochondrial membrane potential and reduced mitochondrial functionality than non-metastatic primary tumors.
[Cancer Research]
Chuang, C.-H., Dorsch, M., Dujardin, P., Silas, S., Ueffing, K., Hölken, J. M., Yang, D., Winslow, M. M., & Grüner, B. M. (2020). Altered mitochondria functionality defines a metastatic cell state in lung cancer and creates an exploitable vulnerability. Cancer Research. https://doi.org/10.1158/0008-5472.CAN-20-1865 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Glutathione S‑Transferase ω 1 Promotes the Proliferation, Migration and Invasion, and Inhibits the Apoptosis of Non‑Small Cell Lung Cancer Cells, via the JAK/STAT3 Signaling Pathway

Scientists investigated the role of glutathione S‑transferase ω 1 (GSTO1) in non‑small cell lung cancer and to determine the potential molecular mechanism. GSTO1 expression levels in A549 cells were knocked down using short hairpin RNA and GSTO1 overexpression in H2122 cells was achieved using cDNA constructs.
[Molecular Medicine Reports]
Wang, K., Zhang, F.-L., & Jia, W. (2021). Glutathione S‑transferase ω 1 promotes the proliferation, migration and invasion, and inhibits the apoptosis of non‑small cell lung cancer cells, via the JAK/STAT3 signaling pathway. Molecular Medicine Reports, 23(1), 1–1. https://doi.org/10.3892/mmr.2020.11709 Cite
AbstractFull Article
Bookmark

No account yet? Register

0
Share

Dysregulated Glutamate Transporter SLC1A1 Propels Cystine Uptake via Xc- for Glutathione Synthesis in Lung Cancer

The authors report that glutamate transporters, in particular SLC1A1, were tightly intertwined with cystine uptake and glutathione biosynthesis in lung cancer cells.
[Cancer Research]
Abstract
Bookmark

No account yet? Register

0
Share
Share